--- title: "Core Laboratories Delays 2025 Annual 10-K Filing" type: "News" locale: "en" url: "https://longbridge.com/en/news/277706490.md" description: "Core Laboratories (CLB) has announced a delay in filing its 2025 Annual Report (Form 10-K) due to the need for additional time to complete complex accounting analyses, particularly regarding income tax issues across multiple jurisdictions. The delay may impact financial statements, including income tax receivable and deferred tax assets. Management is also evaluating internal controls, which must be completed before filing. The company has confirmed compliance with other reporting obligations and emphasizes ongoing efforts to resolve internal control matters. The latest analyst rating for CLB stock is a Hold with a $20.00 price target." datetime: "2026-03-04T01:23:52.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277706490.md) - [en](https://longbridge.com/en/news/277706490.md) - [zh-HK](https://longbridge.com/zh-HK/news/277706490.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277706490.md) | [繁體中文](https://longbridge.com/zh-HK/news/277706490.md) # Core Laboratories Delays 2025 Annual 10-K Filing Core Laboratories ( (CLB) ) has released a notification of late filing. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Core Laboratories Inc. has filed a Form 12b-25 after delaying its Form 10-K (Yearly Report) for the year ended December 31, 2025, notifying investors that its annual filing will not be made on time. The late notice covers its Annual Report on Form 10-K (Yearly Report) and is specific to the company’s 2025 fiscal year results. Management says the delay stems from the need for additional time to complete complex accounting analyses, particularly around income tax issues tied to operations in multiple jurisdictions, including international markets. The company is also compiling supporting documentation and finalizing management’s evaluation of its income tax accounting treatment. Core Laboratories flags that these tax-related reviews could have a material, non-cash impact on its financial statements, though the exact effect cannot yet be determined. The accounts that may be impacted include income tax receivable, deferred tax assets and liabilities, and income tax expense, which could shift how investors view the company’s tax position rather than its cash earnings. The company further discloses that management may conclude there is a significant deficiency or even a material weakness in internal control over financial reporting and disclosure controls as of December 31, 2025. That internal control evaluation must be completed before the Form 10-K (Yearly Report) is filed, adding another layer of work before the annual numbers can be released. Notably, Core Laboratories states that the delay is not due to disagreements with its independent registered public accounting firm over accounting principles, disclosure, or audit procedures. The company also confirms that all other required periodic reports over the past 12 months have been filed, limiting concerns about a broader pattern of noncompliance. The company does not commit to filing the Form 10-K (Yearly Report) within the standard 15-day extension window often used with such notices, leaving the exact filing date uncertain. However, it indicates that management has been working diligently to finalize the annual financial statements and related internal control assessments. Core Laboratories cautions investors that some of the statements in this notification are forward-looking and subject to risks and uncertainties that could cause actual results to differ. These include the timing of the Form 10-K (Yearly Report) filing and the final outcome of its tax accounting review, with risk factors cross-referenced to prior SEC filings, including past Form 10-K (Yearly Report) and Form 10-Q (Quarter Report) reports. The notification emphasizes the company’s ongoing efforts to complete its review and remain compliant with SEC reporting obligations, including resolving any internal control matters it identifies. The filing is signed on behalf of Core Laboratories Inc. by Chief Financial Officer Christopher S. Hill on March 3, 2026, underscoring executive-level responsibility for the disclosure and the remediation process. The most recent analyst rating on (CLB) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Core Laboratories stock, see the CLB Stock Forecast page. **Spark’s Take on CLB Stock** According to Spark, TipRanks’ AI Analyst, CLB is a Neutral. The score is driven primarily by improving profitability and a strengthened balance sheet, tempered by inconsistent/declining 2025 cash flow. Technicals are broadly supportive over longer timeframes but neutral in the near term, while valuation looks somewhat expensive on P/E despite a very high dividend yield. The latest earnings call adds a mixed outlook with constructive guidance but notable near-term cost and macro headwinds. To see Spark’s full report on CLB stock, click here. **More about Core Laboratories** Core Laboratories Inc. is a Houston-based company that provides reservoir description, production enhancement and related services to the oil and gas industry worldwide. The company operates across multiple jurisdictions, including significant international operations, which introduces complex accounting and tax considerations into its financial reporting. **Average Trading Volume:** 381,178 **Technical Sentiment Signal:** Hold **Current Market Cap:** $804.6M ### Related Stocks - [Core Laboratories Inc. (CLB.US)](https://longbridge.com/en/quote/CLB.US.md) ## Related News & Research - [CORE LAB ANNOUNCES IMPACT OF THE MIDDLE EAST CONFLICT TO FIRST QUARTER 2026 GUIDANCE | CLB Stock News](https://longbridge.com/en/news/280215130.md) - [Society Pass Delays Annual 10-K Yearly Filing](https://longbridge.com/en/news/281287662.md) - [Polar Power Delays Annual 10-K Filing](https://longbridge.com/en/news/281283373.md) - [AppYea Delays Annual 10-K Filing Briefly](https://longbridge.com/en/news/281286342.md) - [Bioxytran Delays Annual 10-K Filing](https://longbridge.com/en/news/281395210.md)